BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar

Published on :

BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first time BFI-751 has been administered to humans, as authorized by the Ethics Committees in both Australia and New Zealand.